Phase Ib trial of selinexor (SEL) in combination with nivolumab (NIVO) alone or nivolumab plus ipilimumab (NIVO+IPI) in patients (pts) with advanced malignancies: The renal cell carcinoma (RCC) experience.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Omar Alhalabi, Nizar M. Tannir, Hassan Ahmed Momin, Bulent Yilmaz, Bettzy Stephen, Chinenye Lynette Ejezie, Justin Tyler Moyers, Serdar A Gurses, Jeffrey How, Siqing Fu, Jordi Rodon Ahnert, David S. Hong, Sarina Anne Piha-Paul, Vivek Subbiah, Ecaterina Elena Dumbrava, Daniel D. Karp, Filip Janku, Funda Meric-Bernstam, Aung Naing
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286296279